Catalog No.
Product Name
Application
Product Information
Citations
-
PI3Kδ Inhibitor
LAS195319 is a potent and orally active inhibitor of PI3Kδ, exhibiting an IC50 of 0.5 nM. This compound demonstrates high selectivity against a wide array of proteins, lipid kinases, and GPCRs. LAS195319 effectively inhibits the infiltration of neutrophils and eosinophils, making it a valuable tool for research into respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). -
PI3Kδ Inhibitor
IHMT-PI3Kδ-372 is a highly selective inhibitor of PI3Kδ, exhibiting an IC50 of 14 nM. This compound demonstrates significant selectivity over other class I PI3Ks, with 56 to 83-fold differences, as well as over various protein kinases. IHMT-PI3Kδ-372 is suitable for research applications related to chronic obstructive pulmonary disease (COPD), enabling investigations into therapeutic strategies targeting this pathway. -
PI3K Inhibitor
Isopsoralidin is a phosphatidylinositol 3-kinase (PI3K) inhibitor that demonstrates potentially hepatotoxic properties and exhibits inhibitory activity on CYP2D6. This compound plays a significant role in research focused on cell signaling pathways related to cancer and metabolic disorders. Its unique mechanism of action makes it a valuable tool for studying PI3K-related biological processes and evaluating therapeutic approaches involving PI3K modulation. -
PI3K Kinase Ligand
HL-2 is a selective ligand for the phosphoinositide 3-kinase (PI3K) kinase, utilized in the synthesis of proteolysis-targeting chimeras (PROTACs). Its role in modulating PI3K activity makes it a valuable tool for studying signal transduction pathways and cancer biology. HL-2's application extends to drug development and the investigation of therapeutic strategies targeting PI3K-related diseases. -
PI3K/mTOR Inhibitor
DS-7423 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 15.6 nM for PI3Kα and 34.9 nM for mTOR. This compound demonstrates significant anti-tumor activity, making it a valuable tool for research into cancer biology and potential therapeutic strategies. Its ability to inhibit key signaling pathways involved in cell growth and survival positions DS-7423 as a promising candidate for further exploration in oncology studies. -
PI3K/mTOR Inhibitor
PI3K-IN-37 is a potent inhibitor of the PI3K family, specifically targeting PI3K α, β, and δ isoforms with IC50 values of 6, 8, and 4 nM, respectively. Additionally, PI3K-IN-37 demonstrates strong inhibition of mTOR with an IC50 of 4 nM. This compound is valuable for research applications involving cancer biology, metabolic disorders, and signaling pathways related to cell growth and survival. -
PI3Kα/mTOR Kinase Inhibitor
PI3K-IN-22 is a potent dual inhibitor of the PI3Kα and mTOR kinases, with IC50 values of 0.9 nM and 0.6 nM, respectively. This compound exhibits substantial biological activity, making it valuable for investigating the roles of these pathways in cancer research. PI3K-IN-22 can facilitate the study of tumor growth and response to therapy, contributing to the understanding of oncogenic signaling and potential treatment strategies. -
Dual PI3K/mTOR Inhibitor
PKI-179 hydrochloride is a potent dual inhibitor of the PI3K and mTOR signaling pathways, demonstrating IC50 values of 8 nM for PI3K-α, 24 nM for PI3K-β, 74 nM for PI3K-γ, 77 nM for PI3K-δ, and 0.42 nM for mTOR. This compound is effective against mutant variants E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride has been shown to exhibit significant anti-tumor activity in vivo, making it a valuable tool for cancer research and therapeutic development targeting PI3K/mTOR pathways. -
PI3K/mTOR Inhibitor
SN32976 is a potent and selective inhibitor of class I phosphoinositide 3-kinases (PI3K) and mTOR, exhibiting IC50 values of 15.1 nM for PI3Kα, 461 nM for PI3Kβ, 110 nM for PI3Kγ, 134 nM for PI3Kδ, and 194 nM for mTOR. This compound demonstrates significant selectivity against a wide panel of 442 kinases. SN32976 is primarily utilized in cancer research, showcasing notable anticancer activity that makes it a valuable tool for studying PI3K/mTOR pathway modulation. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-13 sodium is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mTOR kinase, demonstrating oral bioavailability. This compound exhibits significant biological activity in the modulation of cellular growth and metabolism, making it a valuable tool in research related to sexual dysfunction, solid tumors, and idiopathic pulmonary fibrosis (IPF). Its dual inhibition profile presents opportunities for therapeutic exploration in various disease contexts. -
PI3K/mTOR inhibitor
PI3K-IN-18 is a potent inhibitor of the PI3K/mTOR signaling pathway, selectively targeting PI3K-α and mTOR with IC50 values of 41 nM and 49 nM, respectively. This compound exhibits significant biological activity by disrupting key signaling processes involved in cell growth and proliferation. PI3K-IN-18 is valuable for research applications focused on cancer biology, metabolism, and therapeutic strategies targeting the PI3K/mTOR axis. -
PI3K Inhibitor
PI3Kα/mTOR-IN-1 is a selective dual inhibitor targeting PI3Kα and mTOR, exhibiting an IC50 of 7 nM for PI3Kα in cellular assays. It demonstrates Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in cell-free assays, respectively. This compound is instrumental in studies related to cancer biology and signal transduction, making it valuable for research involving the modulation of PI3K/mTOR pathways. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-9 is a potent inhibitor targeting both the PI3K and mTOR pathways, exhibiting IC50 values of 38 nM for mTOR (in phospho-S6 cellular assays) and 6.6 μM, 6.6 μM, and 0.8 μM for PI3Kα, PI3Kγ, and PI3Kδ, respectively. This compound demonstrates significant biological activity in modulating cellular growth and metabolism, making it a valuable tool for research on cancer and other diseases characterized by dysregulated PI3K/mTOR signaling. Its application in various cellular models facilitates the exploration of therapeutic strategies in oncology and other fields of biomedical research. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-5 selectively targets both phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), demonstrating IC50 values of 86.9 nM for PI3K and 14.6 nM for mTOR. This dual inhibition has significant implications for cancer research, as it can effectively impede cell proliferation and survival in tumor cells. PI3K/mTOR Inhibitor-5 is suitable for studies investigating the PI3K/mTOR signaling pathway and its role in various diseases, particularly in the contexts of oncology and metabolic disorders. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-3 is a potent dual inhibitor of phosphoinositide 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). This imidazoline derivative exhibits significant anti-cancer activity, making it a valuable tool for cancer research. Its ability to modulate key signaling pathways related to cell growth and survival enhances its utility in studying tumor biology and therapeutic strategies. -
PI3Kα/mTOR Inhibitor
PI3Kα-IN-5 is a potent inhibitor of the PI3Kα and mTOR pathways, exhibiting IC50 values of 0.7 nM and 3.3 nM, respectively. This compound is valuable for research focused on colorectal cancer, offering insights into the modulation of these critical signaling pathways. Its specificity and efficacy make it an important tool for investigating the roles of PI3Kα and mTOR in cancer biology. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-12 is a selective inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways, exhibiting IC50 values of 0.06 nM for PI3Kα and 3.12 nM for mTOR. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Additionally, PI3K/mTOR Inhibitor-12 has been shown to possess reduced liver toxicity, enhancing its potential for therapeutic applications in oncology. -
PI3K/mTOR Ligand
PI3K/mTOR ligand-1 is a ligand targeting the PI3K/mTOR pathway, crucial for cell growth and metabolism regulation. It functions as a building block for the synthesis of PROTACs aimed at modulating PI3K/mTOR signaling. This compound is valuable in cancer research and drug discovery efforts focusing on targeted protein degradation and pathway inhibition. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-8 is a potent dual inhibitor of PI3K and mTOR, exhibiting IC50 values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. This compound promotes apoptosis in HCT-116 cells and effectively induces cell cycle arrest at the G1/S phase. It serves as a valuable tool for researchers investigating the roles of PI3K and mTOR signaling in cancer biology and potential therapeutic interventions. -
PI3K Inhibitor
MCX 28 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, functioning as a triple inhibitor of PI3K, mTOR, and PIM kinases. It exhibits low nanomolar activity, making it a valuable tool for studying signaling pathways involved in cancer and other diseases. This compound is particularly useful for research applications focused on the modulation of cell proliferation, survival, and metabolic processes. -
PI3K/mTOR Inhibitor
PI3K/mTOR-IN-18 is a highly selective dual inhibitor targeting PI3Kα and mTOR, with binding affinities of Ki=0.130 nM and Ki=0.111 nM, respectively. This compound effectively blocks the PI3K/AKT/mTOR signaling pathway, resulting in significant inhibition of tumor cell proliferation (IC50=144 nM). PI3K/mTOR-IN-18 is suitable for research involving various solid tumors, including breast cancer and non-small cell lung cancer (NSCLC). -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-14 is a dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), exhibiting IC50 values of 171.4 nM and 10.1 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its inhibition of the PI3K/mTOR signaling pathway can be critical for studies focused on cell proliferation and survival in various cancer models. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent dual inhibitor targeting the PI3K and mTOR pathways. It demonstrates a 4.7-fold increased potency compared to the positive control gedatolisib, with an IC50 of 0.3 μM. At a concentration of 10 μM, PI3K/mTOR Inhibitor-7 effectively suppresses the PI3K/Akt/mTOR signaling pathway. This compound is valuable for research applications focused on cancer biology and related therapeutic development. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-6 is a potent dual inhibitor targeting the phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) pathways. This compound demonstrates enhanced stability in artificial gastric fluids compared to other PI3K/mTOR inhibitors. At a concentration of 10 μM, PI3K/mTOR Inhibitor-6 effectively suppresses the PI3K/Akt/mTOR signaling pathway, highlighting its potential for cancer research applications. -
PI3K inhibitor
PI-540 is a bicyclic thienopyrimidine derivative that functions as an orally active inhibitor of phosphoinositide 3-kinases (PI3K). Demonstrating potent anti-cancer cell proliferation activity, PI-540 selectively inhibits various PI3K isoforms with IC50 values of 10 nM for P110α, 3510 nM for P110β, 410 nM for P110δ, and 33110 nM for P110γ. In addition to its PI3K inhibition, PI-540 also targets mTOR and DNA-PK, with IC50 values of 61 nM and 525 nM, respectively, making it a valuable tool for cancer research and therapeutic development. -
PI3K/mTOR Inhibitor
CC-M-1 is a potent and selective inhibitor of the PI3K/mTOR signaling pathway, targeting PI3Kα/β/γ/δ and mTOR with IC50 values of 0.68, 1.02, 1.03, 8.03, and 15 nM, respectively. This compound demonstrates significant inhibition of proliferation in colorectal cancer cell lines, including HCT-116 (IC50 = 0.38 μM) and HT-29 (IC50 = 1.70 μM). CC-M-1 serves as a valuable tool for researchers investigating colorectal cancer (CRC) therapeutic strategies and the underlying mechanisms of tumorigenesis. -
PI3K/mTOR Inhibitor
PI3K/mTOR Inhibitor-13 is a potent, orally active dual inhibitor targeting phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). This compound demonstrates significant biological activity against various pathologies, including solid tumors, sexual diseases, and idiopathic pulmonary fibrosis (IPF). It serves as a valuable tool for cancer research and therapeutic development related to these conditions. -
PI3K/mTOR Inhibitor
WJD008 is a potent dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), specifically targeting PI3K α and mTOR kinase activities. It exhibits significant antiproliferative and anticlonogenic effects in tumor cells, particularly those with PIK3CA mutations. By disrupting the insulin-like growth factor-I-activated PI3K-Akt-mTOR signaling pathway, WJD008 holds promise for advancing cancer research and therapeutic strategies. -
PI3K Inhibitor
PI3K-IN-30 is a selective inhibitor of phosphoinositide 3-kinases (PI3Ks), demonstrating potent inhibition with IC50 values of 5.1 nM for PI3Kα, 136 nM for PI3Kβ, 30.7 nM for PI3Kγ, and 8.9 nM for PI3Kδ. This compound is suitable for studies investigating PI3K signaling pathways and their implications in cancer and other diseases. Its high specificity and potency make it a valuable tool for biochemical and cellular research focused on PI3K-related mechanisms. -
PI3Kδ Inhibitor
Roginolisib is a selective PI3Kδ inhibitor that exhibits potent activity with an IC50 of 145 nM. This compound demonstrates high selectivity against a broad panel of 278 additional kinases, making it a valuable tool for research in cell signaling pathways. Its application in studies targeting immune responses and cancer biology highlights the importance of PI3Kδ modulation in therapeutic development. -
PI3Kγ Inhibitor
PI3Kγ inhibitor AZ2 selectively targets phosphoinositide 3-kinase gamma (PI3Kγ) with a pIC50 value of 9.3, indicating potent inhibition. This compound is valuable for investigating the role of PI3Kγ in inflammatory and immune diseases, providing insights into potential therapeutic applications. Its specificity makes it a useful tool in biochemical and pharmacological studies related to immune regulation. -
Pan-PI3Ks Ihibitor
AMG 511 is a potent pan-inhibitor of class I phosphoinositide 3-kinases (PI3Ks), demonstrating inhibitory constants (Kis) of 4 nM, 6 nM, 2 nM, and 1 nM for PI3Kα, β, δ, and γ, respectively. This compound effectively suppresses PI3K signaling, as evidenced by a decrease in phosphorylated Akt (Ser473). AMG 511 has shown significant anti-tumor activity in mouse models of glioblastoma, making it a valuable tool for cancer research and therapeutic development. -
PI3K Inhibitor
Duvelisib (R enantiomer) is a selective inhibitor of phosphoinositide 3-kinase (PI3K), targeting the delta and gamma isoforms. It exhibits antitumor activity by inhibiting cell proliferation and promoting apoptosis in various cancer models. This compound is primarily utilized in research focused on cancer treatment, immune response modulation, and signaling pathway analysis. -
PI3Kα Inhibitor
PF-06843195 is a highly selective inhibitor of the PI3Kα isoform, exhibiting an IC50 of 18 nM in Rat1 fibroblasts. With kinase inhibition constants (Kis) of less than 0.018 nM and 0.28 nM for PI3Kα and PI3Kδ respectively, this compound effectively suppresses the PI3K/mTOR signaling pathway. PF-06843195 demonstrates significant antitumor efficacy, making it a valuable tool for research applications targeting cancer biology and therapeutic development. -
PI3KC2α Inhibitor
MIPS-21335 is a selective inhibitor of PI3KC2α, exhibiting an IC50 value of 7 nM. Additionally, it demonstrates inhibition of PI3KC2β, p110α, p110β, and p110δ, with corresponding IC50 values of 43, 140, 386, and 742 nM. MIPS-21335 exhibits significant antithrombotic effects and is valuable for research into cardiovascular and metabolic diseases, including thrombosis and hyperlipidemia. -
PI3Kγδ Inhibitor
AZD8154 is a selective dual inhibitor of the PI3Kγ and PI3Kδ isoforms. By effectively suppressing the activation of these signaling pathways, AZD8154 demonstrates potential in modulating inflammatory responses. This reagent is suitable for research in inflammation and immunology, particularly in studies related to asthma and other related conditions. -
PI3K Inhibitor
PIT-1 is a selective inhibitor of phosphatidylinositol 3,4,5-trisphosphate (PIP3) that targets the PI3K/Akt signaling pathway. By inhibiting PIP3, PIT-1 effectively disrupts cancer cell survival and promotes apoptosis. This compound demonstrates significant antitumor activity in vivo, making it suitable for investigations into cancer therapeutics and signaling pathways involved in oncogenesis. -
PI3Kδ Inhibitor
Leniolisib phosphate is a potent and selective inhibitor of the phosphoinositide 3-kinase delta (PI3Kδ) pathway. This compound exhibits significant biological activity in modulating immune responses, making it a valuable tool for research in immunodeficiency disorders. Its mechanism of action underscores its potential in therapeutic applications targeting underlying immunological defects. -
PI3K Inhibitor
PI3K-IN-31 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), displaying IC50 values of 3.7 nM for PI3Kα, 74 nM for PI3Kβ, 14.6 nM for PI3Kγ, and 9.9 nM for PI3Kδ. Its selective inhibition of these kinases correlates with significant anticancer activity, making it a valuable tool in cancer research. Applications for PI3K-IN-31 include studying the PI3K signaling pathway and evaluating its role in tumorigenesis and therapeutic resistance. -
PI3K
PQR514 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), demonstrating significant anticancer activity. This compound effectively inhibits cancer cell proliferation and exhibits substantial antitumor effects in the OVCAR-3 xenograft model, with required concentrations notably lower than those of other PI3K inhibitors. PQR514 features favorable pharmacokinetic properties and minimal brain penetration, positioning it as an optimized candidate for targeting systemic tumors in cancer research applications. -
PI3Kα Inhibitor
(S)-PI3Kα-IN-4 is a highly selective inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) isoform, demonstrating an IC50 value of 2.3 nM. This compound exhibits significant selectivity, with 38.3-fold preference for PI3Kα over PI3Kβ, and more than 4-fold selectivity compared to PI3Kδ and PI3Kγ. (S)-PI3Kα-IN-4 is suitable for research applications focusing on cancer biology, particularly in studies aimed at understanding the role of PI3Kα in tumorigenesis and therapeutic resistance. -
PI3K Inhibitor
Vulolisib is a potent, orally active inhibitor of phosphatidylinositol 3-kinase (PI3K), demonstrating IC50 values of 0.2 nM for PI3Kα, 168 nM for PI3Kβ, 90 nM for PI3Kγ, and 49 nM for PI3Kδ. This compound exhibits significant antiproliferative and antineoplastic properties, making it a valuable tool for cancer research. Its selective inhibition of PI3K isoforms facilitates investigations into the role of PI3K signaling in various malignancies. -
PI3Kδ/γ Inhibitor
PI3Kδ/γ-IN-1 is a selective inhibitor targeting phosphoinositide 3-kinase delta (PI3Kδ) and gamma (PI3Kγ), demonstrating high potency in inhibiting their activity. This compound plays a pivotal role in the study of hematological malignancies, facilitating research into the underlying molecular mechanisms and potential therapeutic approaches for conditions such as leukemia and lymphoma. Its specificity for PI3Kδ and PI3Kγ makes it an invaluable tool for investigating the contributions of these isoforms in cancer biology. -
PI3Kγ Inhibitor
NVS-PI3-4 is a selective inhibitor of PI3Kγ, playing a crucial role in modulating the PI3K signaling pathway. This compound demonstrates significant inhibitory activity, making it a valuable tool for investigating the mechanisms underlying allergies, inflammatory disorders, and various cancer types. Researchers can utilize NVS-PI3-4 to explore therapeutic strategies aimed at targeting PI3Kγ-related pathways in relevant disease models. -
PI3Kα Inhibitor
Benzoin is a potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) signaling pathway, known for its potential anticancer effects. This compound has been shown to effectively impede the growth of the colon cancer cell line HCT-116, making it a valuable tool for cancer research. Its application in studying PI3Kα-mediated processes provides insights into therapeutic strategies for colon malignancies. -
PI3Kγ Inhibitor
AS-041164 is a selective inhibitor of the PI3Kγ isoform, demonstrating a potent inhibitory effect with an IC50 of 70 nM. This compound exhibits significantly reduced activity against other isoforms, including PI3Kα, PI3Kβ, and PI3Kδ, with IC50 values of 240 nM, 1.45 μM, and 1.70 μM, respectively. AS-041164 is recognized for its anti-inflammatory properties and is applicable in research focused on inflammation-related pathways and diseases. -
PI3Kβ Inhibitor
MIPS-9922 is a potent and selective inhibitor of PI3Kβ, exhibiting an IC50 of 63 nM. This compound demonstrates over 30-fold higher potency for PI3Kβ compared to PI3Kδ. MIPS-9922 effectively disrupts PI3K-mediated activation of platelet glycoprotein αIIbβ3 and platelet adhesion in vitro, making it a valuable tool for studying anti-platelet and anti-thrombotic activities in research applications. -
PI3Kδ Inhibitor
Parsaclisib hydrochloride is a selective inhibitor of PI3Kδ, exhibiting an IC50 of 1 nM in the presence of 1 mM ATP. With approximately 20,000-fold selectivity over other PI3K class I isoforms, this orally active compound is valuable for investigating the biochemical pathways involved in B-cell malignancies. It is particularly useful in research focused on relapsed or refractory forms of these cancers. -
PI3Kα Inhibitor
PI3Kα-IN-4 is a selective, potent inhibitor of the phosphoinositide 3-kinase alpha (PI3Kα) with an IC50 value of 1.8 nM. This orally active compound exhibits significant antitumor activity, making it a valuable tool in cancer research. It is primarily used for investigating the role of PI3Kα in oncogenesis and therapeutic resistance. -
PI3K Inhibitor
PI3K-IN-36 is a potent inhibitor of phosphoinositide 3-kinase (PI3K), a critical enzyme involved in cell signaling pathways. This compound exhibits significant biological activity and is primarily utilized in research focused on follicular lymphoma (FL). Its effectiveness as a PI3K inhibitor makes it a valuable tool for investigating the underlying mechanisms of cancer and testing potential therapeutic strategies.
